Hutchmed (China)

Filter

År

Typ

Språk

2024-11-22 05:30:00 HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

2024-11-20 10:30:00 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

2024-11-06 05:00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

2024-10-31 09:30:00 HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

2024-10-16 06:30:00 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

2024-09-24 09:00:00 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

2024-09-09 02:00:00 HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

2024-08-30 06:30:00 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

2024-08-21 10:30:00 HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Språk